From The BMJ. “Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes.
Data from the yellow card scheme for reporting adverse events to the Medicines and Healthcare Products Regulatory Agency (MHRA) show that up to 31 January 2025 there were 22 deaths from adverse reactions associated with use of GLP-1 agonists for weight loss and 60 linked to use for treating type 2 diabetes.
Commenting on the figures, Alison Cave, MHRA chief safety officer, said, āThe decision to start, continue, or stop treatments should be made jointly by patients and their doctor, based on full consideration of benefits and risks.ā
(Also covered in UK newspaper The Sun here).
